SG Americas Securities LLC Boosts Stake in Renovaro Inc. (NASDAQ:RENB)

SG Americas Securities LLC increased its holdings in shares of Renovaro Inc. (NASDAQ:RENB) by 193.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 51,725 shares of the company’s stock after purchasing an additional 34,090 shares during the period. SG Americas Securities LLC’s holdings in Renovaro were worth $43,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of RENB. State Street Corp grew its position in Renovaro by 3.8% during the third quarter. State Street Corp now owns 1,323,832 shares of the company’s stock valued at $640,000 after buying an additional 48,114 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Renovaro by 347.6% in the third quarter. JPMorgan Chase & Co. now owns 93,010 shares of the company’s stock valued at $45,000 after purchasing an additional 72,230 shares in the last quarter. Finally, Barclays PLC grew its holdings in shares of Renovaro by 315.7% in the third quarter. Barclays PLC now owns 69,531 shares of the company’s stock valued at $34,000 after purchasing an additional 52,804 shares in the last quarter. 71.41% of the stock is currently owned by institutional investors.

Renovaro Stock Up 9.0 %

NASDAQ RENB opened at $0.81 on Friday. The firm has a 50 day moving average of $1.02 and a two-hundred day moving average of $0.76. Renovaro Inc. has a 52 week low of $0.40 and a 52 week high of $3.38. The stock has a market capitalization of $128.39 million, a PE ratio of -0.84 and a beta of 0.63.

Renovaro Company Profile

Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company’s product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.